arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

download Export Data

Pasithea Therapeutics Corp.

KTTA

$0.51 0.00 (-0.68%) at close

24 Visible periods

21 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Pasithea Therapeutics Corp. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $16.4M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -9.1% ↘

FCF / Share $-0.15 ↗

Trailing P/E —

Price / Book 0.3x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 23, 2026.

24-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$218.61K

↑ +1509.7% —

Net Income Profit after all expenses

$-2.87M

↑ +19.5% —

FCF / Share Free cash flow per share

$-0.15

↑ +25.4% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Financial Health ↑

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗
EPS Growth YoY (%)	75.8% Excellent → Excellent Stable Year-over-year change in earnings per share Optimal: > 10%	92.5% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	63.1% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	-502.5% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	76.6% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	100.0% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	90.9% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	85.7% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	N/M	—	-22.2% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	0.0% Caution Caution Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—
Net Income Growth YoY (%)	19.5% Good ↑ Good Improving Year-over-year change in net income	19.5% Good ↑ Good Improving Year-over-year change in net income	-218.2% Weak ↓ Weak Declining Year-over-year change in net income	7.7% Fair ↓ Fair Declining Year-over-year change in net income	7.7% Fair ↓ Fair Declining Year-over-year change in net income	7.7% Fair ↑ Fair Improving Year-over-year change in net income	37.1% Excellent ↑ Excellent Improving Year-over-year change in net income	-9.1% Weak ↓ Weak Declining Year-over-year change in net income	-9.1% Weak ↑ Weak Improving Year-over-year change in net income	-9.1% Weak ↑ Weak Improving Year-over-year change in net income	1.4% Caution ↑ Caution Improving Year-over-year change in net income	-124.7% Weak → Weak Stable Year-over-year change in net income	-124.7% Weak ↑ Weak Improving Year-over-year change in net income	-124.7% Weak ↑ Weak Improving Year-over-year change in net income	N/M	-186.4% Weak → Weak Stable Year-over-year change in net income	-186.4% Weak ↑ Weak Improving Year-over-year change in net income	-186.4% Weak Weak Year-over-year change in net income	—	-3834.2% Weak Weak Year-over-year change in net income	—	—	—	—
FCF Growth YoY (%)	—	85.8% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-67.7% Weak Weak Year-over-year change in free cash flow	-139.1% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗
FCF / Net Income (x)	1.64x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	1.67x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	0.53x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.81x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	—	0.86x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.77x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	—	—	—	—	—	—	3.33x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	1.51x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	1.68x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	-2.79x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	—	0.91x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.69x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗
Return on Invested Capital (%)	-9.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-7.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-14.7% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-20.1% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-19.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-22.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-17.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-13.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-19.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-16.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-17.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-10.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-8.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-6.5% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-7.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-7.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-4.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-3.8% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-3.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-6.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-122.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-48.2% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	-32.8% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%
Return on Capital (%) (%)	-11.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-8.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-17.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-22.8% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-22.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-25.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-20.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-16.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-22.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-18.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-19.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-12.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-10.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-7.6% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-8.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-8.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-5.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-4.7% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-3.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	-6.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—
Return on Common Equity (%) (%)	-5.8% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-138%)	-5.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-135%)	-18.3% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-222%)	-29.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-295%)	-23.5% Weak → Weak Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-257%)	-27.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-283%)	-21.5% Weak → Weak Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-243%)	-21.7% Weak → Weak Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-244%)	-23.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-259%)	-19.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-229%)	-21.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-244%)	-12.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-183%)	-9.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-166%)	-9.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-160%)	-12.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-180%)	-3.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-122%)	-3.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-120%)	-3.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-121%)	1.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-92%)	-3.3% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-122%)	-116.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-879%)	-61.0% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-507%)	—	-41.5% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-377%)

⚖️ Is the balance sheet risky? 2 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗
Interest Coverage (x)	—	-369.11x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	-466.32x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—	—	—	-32.67x Weak Weak Operating income divided by interest expense Optimal: > 5x	-502.90x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—	—	-2507.09x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—
Net Debt (USD)	$-45.66M	$-50.40M	$-55.16M	$-4.12M	$-7.22M	$-5.34M	$-6.92M	$-9.36M	$-7.97M	$-12.01M	$-16.33M	$-19.58M	$-26.65M	$-29.91M	$-33.09M	$-42.40M	$-47.94M	$-50.32M	$-52.97M	$-20.57M	—	—	$-243.65K	$-9.03K

📊 What does each share earn? 6 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗
Revenue per Share (USD)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	$0.01	$0.00	$0.00	—	—	—	—	—	—
Basic EPS, GAAP (USD)	$-0.16	$-0.12	$-0.89	$-0.41	$-0.66	$-1.61	$-2.41	—	—	—	$-0.40	$0.00	$-0.01	$-0.01	$-1.71	$-0.17	$-0.11	$-0.07	$0.12	—	$-0.09	$-0.07	—	—
Free Cash Flow per Share (USD)	$-0.15	$-0.20	—	$-0.39	—	$-1.38	—	—	—	—	—	—	—	—	—	$-0.20	$-0.10	$-0.11	—	—	$-0.06	$-0.05	—	—
Book Value per Share (USD)	$1.49	$2.20	$2.39	$1.64	$2.04	$4.80	$10.60	$17.05	$15.49	$19.06	$22.46	$1.36	$1.36	$1.50	$32.64	$1.76	$1.93	$2.17	$2.23	$1.25	$0.06	$0.11	$0.03	—
Tangible Book Value per Share (USD)	$1.49	$2.20	$2.27	$0.55	$0.93	$1.69	$9.70	$8.69	$6.98	$10.39	$13.63	$1.30	$1.00	$1.13	$25.09	$1.62	$1.78	$2.17	$2.23	$1.25	$0.06	$0.11	$0.03	—
Basic Weighted Avg Shares (shares)	32.10M	24.34M	—	7.44M	5.64M	2.21M	—	1.04M	1.04M	1.04M	—	25.16M	26.13M	26.07M	—	26.55M	23.44M	23.01M	—	—	8.26M	7.95M	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗
Working Capital (USD)	$46.41M	$51.24M	$51.49M	$4.15M	$6.90M	$4.53M	$6.25M	$9.12M	$7.25M	$10.73M	$14.06M	$18.73M	$25.81M	$28.99M	$32.20M	$42.96M	$47.66M	$50.52M	$52.85M	$20.51M	—	—	$241.35K	—
Total Equity (USD)	$49.84M	$54.81M	$55.22M	$12.21M	$15.18M	$12.98M	$14.78M	$17.81M	$16.18M	$19.88M	$23.40M	$28.37M	$35.59M	$39.14M	$42.50M	$46.79M	$51.47M	$49.98M	$51.42M	$16.48M	$470.08K	$900.67K	$241.35K	$33.63K

📋 What is driving earnings? 4 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗
Sales/Revenue/Turnover (USD)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	$218.61K	$13.58K	$13.66K	—	—	—	—	—	—
Depreciation Expense (USD)	—	—	$0.00	$24.05K	$4.00K	$4.17K	$4.72K	—	—	$4.72K	$4.68K	—	—	$4.18K	$4.14K	—	—	$5.01K	—	—	—	—	—	—
Net Income, GAAP (USD)	$-2.87M	$-2.87M	$-10.11M	$-3.56M	$-3.56M	$-3.56M	$-3.18M	$-3.86M	$-3.86M	$-3.86M	$-5.05M	$-3.54M	$-3.54M	$-3.54M	$-5.12M	$-1.57M	$-1.57M	$-1.57M	$630.14K	$-549.61K	$-549.61K	$-549.61K	—	$-13.97K
Operating Cash Flow (USD)	$-4.71M	$-4.79M	$-5.40M	$-2.89M	—	$-3.06M	$-2.44M	—	—	—	—	—	—	—	—	$-5.24M	$-2.38M	$-2.53M	$-1.74M	—	$-499.44K	$-381.85K	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 6 years · 24 quarters

Pasithea Therapeutics Corp.

Analytical Summary

24-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare KTTA with peers